Eileanther
1 known investors
Find your way into Eileanther
863 people in our graph share verified history with the Eileanther team — schools, employers, funds. One of them is your warm intro.
Dominic Jacquessonunlockedknows Iain Dukes · together at University of Oxford (overlapped)
knows the team · via University of Oxford
×2knows the team · via GlaxoSmithKline
×3knows the team · via University of Leeds
×4knows the team · via University of Bath
knows the team · via Amgen
Eilean Therapeutics is a small molecule oncology drug discovery company developing pan-variant therapies that target resistance mechanisms in hematologic malignancies. Founded in 2022, it focuses on creating first- and best-in-class treatments for blood cancers that have developed resistance to existing therapies.
Founders & leadership
ID
JB
John ByrdInterim Chief Medical Officer
NS
Nikolay SavchukCOO
AB
Amy BurdCSO
BL
Brian LedwithChief Development Officer
FP
Fraser PickersgillHead CMC
Investors · 1
Frequently asked questions
- What does Eileanther do?
- Eilean Therapeutics is a small molecule oncology drug discovery company developing pan-variant therapies that target resistance mechanisms in hematologic malignancies. Founded in 2022, it focuses on creating first- and best-in-class treatments for blood cancers that have developed resistance to existing therapies.
- Who founded Eileanther?
- Eileanther was founded by Iain Dukes, John Byrd.
- Who are Eileanther's investors?
- Eileanther's investors include OrbiMed.